NL300889I2 - Trifluridine in combinatie met tipiracilhydrochloride - Google Patents

Trifluridine in combinatie met tipiracilhydrochloride Download PDF

Info

Publication number
NL300889I2
NL300889I2 NL300889C NL300889C NL300889I2 NL 300889 I2 NL300889 I2 NL 300889I2 NL 300889 C NL300889 C NL 300889C NL 300889 C NL300889 C NL 300889C NL 300889 I2 NL300889 I2 NL 300889I2
Authority
NL
Netherlands
Prior art keywords
trifluridine
combination
ftd
dose
tipiracil hydrochloride
Prior art date
Application number
NL300889C
Other languages
English (en)
Other versions
NL300889I1 (nl
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300889(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of NL300889I1 publication Critical patent/NL300889I1/nl
Publication of NL300889I2 publication Critical patent/NL300889I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL300889C 2005-01-26 2017-08-08 Trifluridine in combinatie met tipiracilhydrochloride NL300889I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (2)

Publication Number Publication Date
NL300889I1 NL300889I1 (nl) 2017-08-14
NL300889I2 true NL300889I2 (nl) 2018-01-16

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300889C NL300889I2 (nl) 2005-01-26 2017-08-08 Trifluridine in combinatie met tipiracilhydrochloride

Country Status (19)

Country Link
EP (1) EP1849470B2 (nl)
JP (1) JP5576591B2 (nl)
KR (1) KR101468216B1 (nl)
AU (1) AU2006209547C1 (nl)
CA (1) CA2594713A1 (nl)
CY (2) CY1119393T1 (nl)
DK (1) DK1849470T4 (nl)
ES (1) ES2630002T3 (nl)
FI (1) FI1849470T4 (nl)
HU (2) HUE033306T2 (nl)
LT (2) LT1849470T (nl)
LU (1) LUC00036I2 (nl)
NL (1) NL300889I2 (nl)
PL (1) PL1849470T3 (nl)
PT (1) PT1849470T (nl)
RU (1) RU2394581C2 (nl)
SI (1) SI1849470T1 (nl)
TW (1) TWI362265B (nl)
WO (1) WO2006080327A1 (nl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
HUE033306T2 (hu) 2005-01-26 2017-11-28 Taiho Pharmaceutical Co Ltd Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
ES2587381T3 (es) 2007-04-25 2016-10-24 Cyclacel Limited Uso de sapacitabina para tratar una enfermedad proliferativa
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
EP2303283A2 (en) * 2008-05-15 2011-04-06 Katholieke Universiteit Leuven K.U. Leuven R&D Anti-cancer combination therapy
RU2567723C2 (ru) 2009-07-22 2015-11-10 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
PE20131126A1 (es) 2010-09-02 2013-10-21 Gruenenthal Chemie Forma de dosificacion resistente a alteracion que comprende un polimero anionico
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
DK2736497T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
NO2746404T3 (nl) * 2011-08-16 2018-05-05
TWI503122B (zh) 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
TWI585206B (zh) 2012-03-14 2017-06-01 Nisshin Pharma Inc A method for producing a composition containing a sulfur-containing amino acid
WO2013156453A1 (en) 2012-04-18 2013-10-24 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
RU2630975C2 (ru) 2012-05-16 2017-09-15 Новартис Аг Режим дозирования pi-3 киназы
US9616082B2 (en) * 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including irinotecan hydrochloride hydrate
JP6002835B2 (ja) * 2013-03-27 2016-10-05 大鵬薬品工業株式会社 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
EP2998742A4 (en) * 2013-05-17 2017-01-18 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
DK3042669T3 (da) 2013-09-06 2023-06-12 Taiho Pharmaceutical Co Ltd Antitumormiddel og forstærker af antitumorvirkning
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
KR20170139158A (ko) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
US11612653B2 (en) * 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
WO2017135412A1 (ja) 2016-02-05 2017-08-10 大鵬薬品工業株式会社 重度腎機能障害を有する癌患者に対する治療方法
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
WO2019124544A1 (ja) 2017-12-22 2019-06-27 大鵬薬品工業株式会社 トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE245631T1 (de) 1995-03-29 2003-08-15 Taiho Pharmaceutical Co Ltd Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
ATE284694T1 (de) * 1996-09-24 2005-01-15 Taiho Pharmaceutical Co Ltd Uracilderivate enthaltende krebsmetastasen inhibitoren
HUE033306T2 (hu) 2005-01-26 2017-11-28 Taiho Pharmaceutical Co Ltd Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog

Also Published As

Publication number Publication date
FI1849470T4 (fi) 2024-03-22
LUC00036I1 (nl) 2017-10-02
AU2006209547C1 (en) 2022-04-07
AU2006209547B2 (en) 2011-05-26
HUE033306T2 (hu) 2017-11-28
EP1849470A4 (en) 2010-12-08
TW200637562A (en) 2006-11-01
JPWO2006080327A1 (ja) 2008-06-19
CA2594713A1 (en) 2006-08-03
CY2017029I2 (el) 2018-02-14
SI1849470T1 (sl) 2017-10-30
EP1849470A1 (en) 2007-10-31
PT1849470T (pt) 2017-09-22
CY2017029I1 (el) 2018-02-14
DK1849470T4 (en) 2024-04-02
EP1849470B2 (en) 2024-03-20
RU2394581C2 (ru) 2010-07-20
EP1849470B1 (en) 2017-06-21
JP5576591B2 (ja) 2014-08-20
AU2006209547A1 (en) 2006-08-03
LTC1849470I2 (lt) 2019-10-25
KR20070104559A (ko) 2007-10-26
KR101468216B1 (ko) 2014-12-03
PL1849470T3 (pl) 2017-11-30
NL300889I1 (nl) 2017-08-14
DK1849470T3 (en) 2017-08-14
RU2007132181A (ru) 2009-03-10
LUC00036I2 (nl) 2017-12-01
WO2006080327A1 (ja) 2006-08-03
TWI362265B (en) 2012-04-21
HUS1700032I1 (hu) 2017-09-28
LT1849470T (lt) 2017-07-25
ES2630002T3 (es) 2017-08-17
CY1119393T1 (el) 2018-02-14
LTPA2017024I1 (lt) 2017-08-10

Similar Documents

Publication Publication Date Title
NL300889I2 (nl) Trifluridine in combinatie met tipiracilhydrochloride
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
NO20065878L (no) Terapeutiske forbindelser
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
WO2007056023A3 (en) Thiazole inhibitors targeting resistant kinase mutations
WO2006056711A3 (fr) Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
TW200716628A (en) Novel compounds
SE0401342D0 (sv) Therapeutic compounds
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
UA83832C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение
BRPI0510820A (pt) composição farmacêutica, forma unitária de dosagem e seus usos
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
TW200509909A (en) Use of organic compounds
WO2005082884A3 (en) 2-pyridin-2yl-pyrimidine derivatives useful in the treatment of gastro-esophagea l reflux disease
SE0302571D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005079769A3 (en) Piperazine derivatives for the treatment of endometriosis
TW200626133A (en) Oral medication for twice-daily administration